Veterinary-grade isoflurane API corresponds to the compendial substance 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane, CAS 26675-46-7, molecular formula C3H2ClF5O, and molecular weight 184.49 g/mol. The substance is supplied as a clear, colorless, non-flammable volatile liquid with a specific gravity of 1.496–1.510 at 20 °C and a refractive index of 1.299–1.301 at 20 °C. Compendial assay by gas chromatography with flame ionization detection is 99.5–100.5% on the anhydrous basis, with water content not exceeding 0.1% and residue on evaporation not exceeding 0.010%. The descriptor for this API lists tablet, injection, capsule, powder, granule, premix, and solution processing routes; however, the volatility of isoflurane restricts practical formulation to sealed liquid or inhalation delivery. Neat isoflurane exhibits a boiling point of 48.5 °C at 760 mmHg and a vapor pressure of 238 mmHg at 20 °C (31.7 kPa). Open-container unit-dose processing therefore operates outside the content-uniformity retention window defined by USP <905> for low-dose solid forms where the active is present at less than 5% w/w. Published data for direct compression of isoflurane into tablets is limited; the absence of a stabilized solid-state polymorph precludes conventional tablet or capsule manufacture without specialized cold-fill technology. The API is shipped in amber glass or fluorinated high-density polyethylene containers with polytetrafluoroethylene-lined closures to prevent headspace moisture ingress. Standard industrial pack sizes are 250 mL and 1 L amber glass bottles; bulk quantities are supplied in fluorinated HDPE drums under a nitrogen headspace.

What Distinguishes Veterinary-Grade Isoflurane from Human-Grade Material?

The molecular entity is identical across human and veterinary listings; the separation is maintained through label claim, distribution control, and species-specific labeling rather than through any difference in chemical purity. Both grades meet the harmonized USP and European Pharmacopoeia monographs for Isoflurane. Veterinary product documentation replaces human minimum alveolar concentration (MAC) values with species-specific MAC data. Reported MAC values at sea level for dogs range from 1.3% to 1.5%, for cats approximately 1.6%, and for horses approximately 1.31%. These values shift with body temperature, age, pregnancy, and concurrent administration of alpha-2 agonists or opioids. For example, xylazine premedication in horses lowers isoflurane MAC by 20–30%, a reduction that must be accounted for during vaporizer setting selection. Manufacturing facilities comply with current Good Manufacturing Practice under 21 CFR 211, and residual solvent limits follow ICH Q3C where applicable. No compendial allowance exists for reduced purity in veterinary material; a release assay below 99.5% is out-of-specification for both markets.

A typical density determination on a Mettler Toledo DE40 density meter at 20 °C yields 1.50 g/mL. Dynamic viscosity at 25 °C is approximately 0.33 mPa·s, which permits transfer through 316L stainless steel filling nozzles with an inner diameter of 1.0 mm or greater. The saturated headspace concentration calculated from the vapor pressure ratio is 31.3% v/v at 20 °C; therefore, open-container processing leads to gravimetric dispensing errors that fall outside a ±2% tolerance unless the reservoir is chilled below 15 °C, where vapor pressure falls to approximately 120 mmHg. Aqueous solubility is below 1% w/v, so water-based injection vehicles do not achieve therapeutic concentrations without the addition of non-aqueous co-solvents. Gas-liquid partition behavior favors rapid equilibration with the vapor phase, which is the basis for vaporizer-delivered administration. No compendial monograph currently defines a finished injectable isoflurane dosage form; published parenteral data in domestic species is limited to experimental protocols. The same volatility constraint applies to capsule filling: hard gelatin capsules filled with neat isoflurane would be expected to exhibit weight loss exceeding 10% within 24 hours at 25 °C based on the vapor pressure differential, unless the capsule shell is hermetically sealed and the fill volume is less than 0.5 mL.

Comparative Physicochemical and MAC Data Across Volatile Anesthetics

The following table compares isoflurane with three halogenated volatile anesthetics commonly stocked in veterinary practice. Values are compiled from published peer-reviewed veterinary pharmacology sources and product safety data sheets.

Isoflurane occupies an intermediate position in both blood/gas solubility and vapor pressure. Its lower vapor pressure relative to desflurane permits use of a standard precision vaporizer without an electrically heated sump, while its higher blood/gas partition coefficient relative to sevoflurane yields slower mask induction and recovery. Unlike halothane, isoflurane does not sensitize the myocardium to catecholamine-induced arrhythmias to the same degree, and its oxidative metabolism through cytochrome P450 2E1 is below 0.2% of absorbed dose. The higher oil/gas coefficient of 90 relative to sevoflurane (47) indicates greater lipid solubility, which contributes to a more sustained redistribution phase and a slightly prolonged emergence in obese animals. Differences in boiling point also determine vaporizer design; desflurane requires an electrically heated, pressurized vaporizer because its vapor pressure of 669 mmHg at 20 °C approaches atmospheric pressure, while isoflurane is delivered accurately with a variable-bypass plenum vaporizer over the full dial range of 0.5–5.0%.

Dosing in dogs typically begins with vaporizer settings of 5.0% for induction and 1.5–2.5% for maintenance under oxygen flow rates of 0.8–1.5 L/min in a circle rebreathing system. Horses require 3.0–5.0% induction and 1.5–2.5% maintenance depending on body weight and concurrent xylazine or romifidine premedication. In rabbits, reported MAC values range from 2.0% to 2.9%, and in psittacine birds from 1.3% to 1.7%, although avian anesthesia requires active ventilation support and heated environments. The low metabolism below 0.2% minimizes hepatotoxic risk compared with halothane; recovery time is prolonged relative to sevoflurane because the blood/gas partition coefficient of 1.4 delays redistribution from muscle and adipose compartments. Precision, temperature-compensated, out-of-circuit vaporizers of the variable-bypass type maintain output within ±0.2% absolute at dial settings below 2.0%. Intraoperative monitoring of end-tidal isoflurane concentration by infrared absorption spectrophotometry should be used to adjust vaporizer output, as delivered concentration varies with fresh gas flow, back pressure, and ambient temperature. At fresh gas flows below 0.5 L/min in a circle system, the difference between the vaporizer dial setting and the inspired concentration can exceed 0.5% due to uptake and circuit dilution.

Isoflurane is not approved for use in food-producing species in several jurisdictions, including the United States, where the Animal Medicinal Drug Use Clarification Act permits extra-label use only under specific conditions with a defined withdrawal period. Published residue depletion data for isoflurane in cattle and swine are limited; the volatile nature of the compound suggests rapid pulmonary elimination, but no official maximum residue limit has been established by the Codex Alimentarius Commission. In equine practice, isoflurane is widely used because the treated horse is typically not intended for human consumption. When administration to food-producing animals is considered, the veterinarian must determine a withdrawal interval based on 21 CFR 530 and available pharmacokinetic data; published data for this specific configuration is limited. The product should not be used in closed-circuit systems without adequate activated charcoal scavenging of waste gas, because occupational exposure limits for halogenated anesthetic agents are generally set below 2 ppm as an eight-hour time-weighted average.

When Desiccated Carbon Dioxide Absorbers Contact Isoflurane

Carbon monoxide generation from isoflurane interaction with standard carbon dioxide absorbents is documented only under conditions of absorbent desiccation. Fresh soda lime typically contains 13–15% water; when the water content drops below 1.5% through prolonged dry gas flow, the difluoromethoxy moiety of isoflurane undergoes base-catalyzed elimination, releasing carbon monoxide and trifluoroacetic acid derivatives. Bench-top studies have recorded canister temperatures exceeding 45 °C and headspace carbon monoxide concentrations above 100 ppm within 30 minutes when desiccated barium hydroxide lime is exposed to 2.0% isoflurane at a flow of 0.5 L/min. The reaction rate accelerates with decreasing absorbent water content and increasing dry gas flow duration; dry gas flow over a weekend is a commonly reported predisposing event. The clinical consequence is an elevated carboxyhemoglobin fraction; values above 10% are clinically significant, and levels above 25% are consistent with severe carbon monoxide poisoning. Preventive measures include replacement of absorbent when the ethyl violet indicator changes color from white to violet, avoidance of long-duration dry gas flow through the absorber, use of carbon dioxide absorbents without strong alkali metals, and continuous end-tidal carbon monoxide monitoring when low-flow anesthesia exceeds two hours. The veterinary anesthesia workstation should comply with ISO 80601-2-13:2011 for absorbent bypass and breathing system integrity. Desflurane shares this desiccated-absorber carbon monoxide risk, while sevoflurane forms fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) under similar low-flow conditions. Halothane produces negligible carbon monoxide but remains limited by hepatotoxic metabolite formation.

Release Testing Confirms Conformance to USP and EP Monographs

Each batch is accompanied by a certificate of analysis generated from the tests listed below. Methods follow the current USP and European Pharmacopoeia monographs for Isoflurane. Analytical method validation for the gas chromatographic assay typically reports linearity over the range 50–150% of the nominal concentration with a correlation coefficient greater than 0.999, injection repeatability with a relative standard deviation below 0.5%, and a limit of quantitation at or below 0.05% for related impurities.

Packaging and storage conditions are verified on a per-batch basis. The product is filled under nitrogen into light-resistant containers and stored at controlled room temperature of 15–30 °C. Storage at temperatures above 40 °C accelerates the formation of acidic degradation products; the resulting free fluoride can etch glass surfaces and corrode aluminum components in vaporizer chambers. The product remains non-flammable under normal anesthesia delivery conditions; no flash point is observed by the closed-cup method up to 60 °C. Bulk-liquid contact with strong bases, particularly potassium hydroxide-containing soda lime, should be limited to the closed absorber circuit because the reaction is exothermic. No antioxidant or preservative is required; the neat liquid is chemically stable for at least 24 months when stored unopened at 25 °C.